Effect Evaluation of Strychnos nux-vomica L.with Integrative Methods for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma Patients:A Self-Controlled Clinical Trial

• 作者: DAI Tie-ying CHEN Chu-chu HONG Li-li Ge Hang-ping PEI Jun LYU Wen-qi YANG Xue SHEN Jian-ping HU Zhi-ping
• 来源期刊: 中国结合医学杂志（英文版）
• 年，卷（期）: 2021,（2）
• 所属期刊栏目: Clinical Experience
• 页码范围: 131-136
• 页数: 6页
• 语种: 英文
• DOI: 10.1007/s11655-020-3196-2

摘要

Objective:To explore the clinical effect and adverse reactions of Strychnos nux-vomica in bortezomib-induced peripheral neuropathy(BIPN)of patients with multiple myeloma(MM).Methods:A total of 19 MM patients with BIPN were enrolled and Nux Vomica Capsule(NVC,0.4 g,thrice daily)were orally administrated for 30 days.Comparative analysis on parameters between pre-and post-therapy,including peripheral neuropathy(PN)grade,neurotoxicity score,Chinese medicine(CM)syndrome score,total neuropathy score(TNS),coagulation function,and serum nerve growth factor(NGF)levels were conducted.The adverse events were monitored.Results:In BIPN of MM patients who received NVC,PN grade was lowered,neurotoxicity score was obviously decreased(P≤0.01),and both CM syndrome score and TNS were remarkably decreased(P＜0.01).After the therapy,activated partial thromboplastin time was prolonged(P＜0.01)and fibrinogen was declined(P＜0.05),showing improvement in the hypercoagulable state of patients.No significant difference of NGF recovery degrees was detected between pre-and post-therapy(P＞0.05).No evident adverse reactions were observed during the course of treatment.Conclusion:Strychnos nux-vomica L.has significantly effect with a good safety in treatment of BIPN in MM patients.